Pre-Clinical Data with ALN-AGT for Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia

Pre-Clinical Data with ALN-AGT for Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia

We announced a new program, ALN-AGT, an RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia. Pre-clinical data were presented at the American Heart Association’s High Blood Pressure Research 2014 Scientific Sessions, held September 9 – 12, 2014, in San Francisco. Data from experiments in an established rat model of preeclampsia demonstrated that an RNAi therapeutic targeting AGT ameliorates the clinical sequelae of preeclampsia and improves outcomes for the fetus.  This treatment approach has the potential for selective delivery to the pregnant mother without fetal drug exposure, as our study confirmed undetectable siRNA levels in the fetus.




New therapies are clearly needed to prevent or treat HDP, including preeclampsia, since existing small molecule anti-hypertensive drugs readily cross the placental barrier and can cause fetal toxicity. We look forward to advancing ALN-AGT as a highly innovative approach for the management of HDP and preeclampsia.



SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.